Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiveSpo Navax for Acute Respiratory Disease in Children with RSV
NCT05164692Completed
- Sponsor
- National Hospital of Pediatrics
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of LiveSpo Navax in respiratory syncytial virus infection (RSV) (2 arms), sponsored by National Hospital of Pediatrics. Primary endpoint: Percentage of patients with free respiratory symptoms. Started Aug 2020; status: completed.
02
Drugs
LiveSpo Navax
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05164692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164692.